Business
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
Tel Aviv, Israel / Vancouver, Canada, April 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the
About this update from Clearmind Medicine Inc.
[{"type":"text","content":"Tel Aviv, Israel / Vancouver, Canada, April 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company\"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has formed a Data and Safety Monitoring Board (DSMB) to oversee the company's first in human clinical trial, for Alcohol Use Disorder (\"AUD\") treatment. The DSMB – an independent group of experts– includes a specialist in internal medicine, a specialist in psychiatry, and a biostatistician. The DSMB is a committee of experts responsible for reviewing clinical trial data on an ongoing basis to ensure the safety of study subjects and validity and integrity of the data. “As we are approaching the beginning of our clinical trials in AUD, the formation of this committee is in line with the company's policy, which places patient safety at the center, throughout all stages of product development and use.\" said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. About Clearmind Medicine Inc. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of fourteen patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol \"CMND\" and the Frankfurt Stock Exchange under the symbol “CWY.” For further information visit: https://www.clearmindmedicine.com or contact: Investor Relations [email protected]: (604) 260-1566 General Inquiries [email protected] FORWARD-LOOKING STATEMENTS: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities ...